Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WVT 078

Next Previous
Search
Drug Profile

WVT 078

Alternative Names: WVT-078

Latest Information Update: 24 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 02 Dec 2024 Novartis Pharmaceuticals terminated a phase-I clinical trials in Multiple myeloma (Second-line therapy or greater, Monotherapy) in Australia, Germany, Israel, Italy, Japan, Norway, Spain, USA (IV) due to business reasons and was not based on any safety or tolerability concerns(NCT04123418)
  • 29 Jan 2024 Phase I development is ongoing in Australia, Germany, Israel, Italy, Japan, Norway, Spain, USA (NCT04123418)
  • 09 Dec 2023 Efficacy data from the phase I trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top